Characterizing the protective component of the αβ T cell response to transplantable squamous cell carcinoma

Journal of Investigative Dermatology

Volumn 122, Issue 3, 2004, Pages 699-706

  Girardi, Michael ^a   Oppenheim, David ^b   Glusac, Earl J ^a   Filler, Renata ^a   Balmain, Allan ^c   Tigelaar, Robert E ^a   Hayday, Adrian C ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GUY S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CD4; CD8; Interferon ; NKG2D; Tumor immunology

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; LIGAND; NATURAL KILLER CELL RECEPTOR NKG2D; PROTEIN RAE 1; RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSPOT ASSAY; IMMUNOCOMPETENCE; KERATINOCYTE; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE; TUMOR GROWTH; TUMOR IMMUNOLOGY;

EID: 1842689931     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0022-202X.2004.22342.x     Document Type: Article

References (59)

1. Bacso Z, Bene L, Damjanovich L, Damjanovich S: INF-gamma rearranges membrane topography of MHC-I and ICAM-1 in colon carcinoma cells. Biochem Biophys Res Commun 290:635-640, 2002
2. Banchereau J, Palucka AK, Dhodapkar M, et al: Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 61:6451-6458, 2001
3. Beatty GL, Paterson Y: IFN-gamma can promote tumor evasion of the immune system in vivo by down-regulating cellular levels of an endogenous tumor antigen. J Immunol 165:5502-5508, 2000
4. Belkaid Y, Piccirillo CA, Mendez S, Shevach EM, Sacks DL: CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 420:502-527, 2002
5. Berard F, Blanco P, Davoust J, et al: Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J Exp Med 4; 192:1535-1544, 2000
6. Blankenstein T, Qin Z: The role of IFN-gamma in tumor transplantation Immunity and inhibition of chemical carcinogenesis. Curr Opin Immunol 15:148-154, 2003
7. Caulin C, Bauluz C, Gandarillas A, Cano A, Quintanilla M: Changes in keratin expression during malignant progression of transformed mouse epidermal keratinocytes. Exp Cell Res 204:11-21, 1993
8. Cerwenka A, Baron JL, Lanier LL: Ectopic expression of retinoic acid early gene-1 (Rae-1) permits NK cell mediated rejection of a MHC class I(+) tumor in vivo. Proc Natl Acad Sci USA 98:11521-11526, 2001
9. Chin YE, Kitagawa M, Kuida K, Flavell AR, Fu XY: Activation of the STAT signaling pathway can cause expression of caspase-1 and apoptosis. Mol Cell Biol 17:5328-5337, 1997
10. Cohn BA: Squamous cell carcinoma: Could it be the most common skin cancer? J Am Acad Dermatol 39:134-136, 1998
11. Coughlin CM, Salhany KE, Gee MS, et al: Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 9:25-34, 1998
12. Coussens LM, Tinkle CL, Hanahan D, Werb Z: MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103:481-490, 2000
13. Dalton DK, Pitts-Meek S, Keshav S, Figari IS, Bradley A, Stewart TA: Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science 259:1739-1745, 1993
14. + T cells. J Exp Med 197:1017-1028, 2003
15. Diaz-Guerra M, Haddow S, Bauluz C, Jorcano JL, Cano A, Balmain A, Quintanilla M: Expression of simple epithelial cytokeratins in mouse epidermal keratinocytes harboring Harvey ras gene alterations. Cancer Res 52:680-687, 1992
16. Diefenbach A, Jensen ER, Jamieson AM, Raulet DH: Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 413:165-171, 2001
17. Dudley ME, Wunderlich JR, Robbins PF, et al: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298:850-854, 2002
18. Dunn GP, Bruce AT, Ikeda H, Old L, Schreiber RD: Cancer immunoediting: From immunosurveillance to tumor escape. Nat Immunol 300:991-998, 2002
19. Enzler T, Gillessen S, Manis JP, et al: Deficiencies of GM-CSF and interferon {gamma} link inflammation and cancer. J Exp Med 197:1213-1219, 2003
20. Euvrard S, Kanitakis J, Pouteil-Noble C, Claudy A, Touraine JL: Skin cancers in organ transplant recipients. Ann Transplant 2:28-32, 1997
21. Fetscher S, Finke J, Engelhardt R, Mertelsmann R, Lange W: Early-onset secondary malignancies after high-dose chemotherapy and autologous hematopoietic stem cell transplantation. Ann Hematol 74:73-77, 1997
22. Fusenig NE, Amer SM, Boukamp P, Worst PK: Characteristics of chemically transformed mouse epidermal cells in vitro and in vivo. Bull Cancer 65:271-279, 1978
23. Galvao MM, Sotto MN, Kihara SM, Rivitti EA, Sabbaga E: Lymphocyte subsets and Langerhans cells in sun-protected and sun-exposed skin of immunosuppressed renal allograft recipients. J Am Acad Dermatol 38:38-44, 1998
24. + T cells to different stages of chemically-induced skin cancer. J Exp Med 198:747-755, 2003
25. Girardi M, Herreid P, Tigelaar RE: Specific suppression of lupus-like graft-versus-host disease using extracorporeal photochemical attenuation of effector lymphocytes. J Invest Dermatol 104:177-182, 1995
26. Girardi M, Oppenheim DE, Steele CR, et al: Regulation of cutaneous malignancy by γδ T cells. Science 294:605-609, 2001
27. Gocinski BL, Tigelaar RE: Roles of CD4+ and CD8+ T cells in murine contact sensitivity revealed by in vivo monoclonal antibody depletion. J Immunol 144:4121-4128, 1990
28. Groh V, Steinle A, Bauer S, Spies T: Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells. Science 279:1737-1740, 1998
29. Groh V, Wu J, Yee C, Spies T: Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419:734-738, 2002
30. Haeffner AC, Zepter K, Elmets CA, Wood GS: Analysis of tumor-infiltrating lymphocytes in squamous cell carcinoma. Arch Dermatol 133:585-590, 1997
31. Hanson HL, Donermeyer DL, Ikeda H, et al: Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity 13:265-276, 2000
32. Hodak E, Jones RE, Ackerman AB: Solitary keratoacanthoma is a squamous-cell carcinoma: Three examples with metastases. Am J Dermatopathol 15:332-342, 1993
33. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H: The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 188:2357-2368, 1998
34. Ibe S, Qin Z, Schuler T, Preiss S, Blankenstein T: Tumor rejection by disturbing tumor stroma cell interaction. J Exp Med 194:1549-1559, 2001
35. Ikeda H, Old LJ, Schreiber RD: The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 13:95-109, 2002
36. Itohara S, Mombaerts P, Lafaille J, et al: T cell receptor delta gene mutant mice: Independent generation of alpha-beta T cells and programmed rearrangements of gamma-delta TCR genes. Cell 72:337-348, 1993
37. Kalos M: Tumor antigen-specific T cells and cancer immunotherapy: Current issues and future prospects. Vaccine 21:781-786, 2003
38. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, Schreiber RD: Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 95:7556-7561, 1998
39. Kerschmann RL, McCalmont TH, LeBoit PE: p53 oncoprotein expression and proliferation index in keratoacanthoma and squamous cell carcinoma. Arch Dermatol 130:181-186, 1994
40. Klein L, Trautman L, Psarras S, et al: Visualizing the course of antigen-specific CD8 and CD4 T cell responses to a growing tumor. Eur J Immunol 33:806-814, 2003
41. Koller BH, Marrack P, Kappler JW, Smithies O: Normal development of mice deficient in beta-2 M MHC class I proteins, and CD8+ T cells. Science 248:1227-1229, 1990
42. Martinez JC, Otley CC, Stasko T, Euvrard S, Brown C, Schanbacher CF, Weaver AL: Defining the clinical course of metastatic skin cancer in organ transplant recipients: A multicenter collaborative study. Arch Dermatol 139:301-306, 2003
43. Marzo AL, Lake RA, Robinson BW, Scott B: T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors. Cancer Res 59:1071-1079, 1999
44. McCarrick JW III, Fames JR, Seong RH, Solter D, Knowles BB: Positive-negative selection gene targeting with the diphtheria toxin A-chain gene in mouse embryonic stem cells. Transgenic Res 2:183-190, 1993
45. Mombaerts P, Clarke AR, Rudnicki MA, et al: Mutations in T-cell antigen receptor genes alpha and beta block thymycyte development at different stages. Nature 360:225-231, 1992
46. Mumberg D, Monach PA, Wanderling S, Philip M, Toledano AY, Schreiber RD, Schreiber H: CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. Proc Natl Acad Sci USA 96:8633-8638, 1999
47. Pardoll DM: Spinning molecular immulogy into successful immunotherapy. Nat Rev Immunol 2:227-238, 2002
48. Patel A, Halliday GM, Cooke BE, Barnetson RS: Evidence that regression in keratoacanthoma is immunologically mediated: A comparison with squamous cell carcinoma. Br J Dermatol 1321:789-798, 1994
49. Paul CF, Ho VC, McGeown C, et al: Risk of malignancies in psoriasis patients treated with cyclosporine: A 5 y cohort study. J Invest Dermatol 1202:211-216, 2003
50. Peto J: Cancer epidemiology in the last century and the next decade. Nature 411:390-395, 2001
51. Qin Z, Blankenstein T: CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity 12:677-686, 2000
52. Qin Z, Kim HJ, Hemme J, Blankenstein T: Inhibition of methylcholanthrene-induced carcinogenesis by an interferon gamma receptor-dependent foreign body reaction. J Exp Med 195:1479-1490, 2002
53. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD: IFN gamma and lymphocytes prevent primary tumour development and shape tumor immunogenicity. Nature 410:1107-1111, 2001
54. Shedlock DJ, Shen H: Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 300:337-339, 2003
55. Siegel CT, Schreiber K, Meredith SC, et al: Enhanced growth of primary tumors in cancer-prone mice after immunization against the mutant region of an inherited oncoprotein. J Exp Med 191:1945-56, 2000
56. Soiffer R, Hodi FS, Haluska F, et al: Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage Colony-stimulated factor by adenovial-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol 21:3343-3350, 2003
57. Sun JC, Bevan MJ: Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 300:339-342, 2003
58. Veness MJ, Quinn DI, Ong CS, Keogh AM, Macdonald PS, Cooper SG, Morgan GW: Aggressive cutaneous malignancies following cardiothoracic transplantation: The Australian experience. Cancer 85:1758-1764, 1999
59. White CW, MacNeil A, Busch DH, Pilip IM, Pamer EG, Harty JT: Perforin-deficient CD8+ T cells: In vivo priming and antigen-specific immunity against Listeria monocytogenes. J Immunol 162:980-988, 1999